Prostate Cancer

E. David Crawford, MD: The Benefits of ConfirmMDx

Dr. Crawford talks about a new epigenetic test that helps to prevent unnecessary biopsies in men with prostate cancer.

Exercise May Cut Prostate Cancer Risk in Whites

By

A new study shows that exercise may reduce the risk of developing prostate cancer in Caucasian men, but not African Americans.

Post-Prostatectomy QoL Associated with Surgeon Variation

Post-Prostatectomy QoL Associated with Surgeon Variation

Significant associations seen in men's urinary and sexual function based on surgeon.

Is radium-223 a game-changer for treatment of CRPC with symptomatic bone metastases?

By

This week, the FDA approved radium-223 injection for the treatment of CRPC with symptomatic bone metastases.

Genetic Analyses Could Reduce the Number of Prostate Biopsies

By

Researchers say they have identified genetic variants that can increase PSA concentrations and prostate cancer risk.

Novel Drug for Metastatic Prostate Cancer Approved

By

Radium-223, a first-in-class drug, travels directly to the site of bone metastases, where it emits alpha particles that exert an anti-tumor effect.

Prostate Cancer Risk Not Higher with TRT Use

By

Researchers studied 850 testosterone-deficient men who received 1,000 mg parenteral testosterone undecanoate six weeks after baseline and then every 12 weeks for up to five years.

Continuous Superior to Intermittent ADT, Study Finds

By

A large, international trial has found intermittent ADT is not equivalent to continuous ADT.

Updated Prostate Cancer Screening Guidelines Announced

By

Shared decision-making about screening recommended for men aged 55-69 years.

Prostate Cancer Deaths Occurring at Older Ages

By

Median survival time from diagnosis improved by a median of 43 months from the pre-PSA to the post-PSA era.

Prostate Cancer Risk Not Elevated with Testosterone Replacement

By

In fact, men on testosterone replacement therapy (TRT) had a lower PCa rate than men not on TRT.

Sildenafil Preserves Erectile Function in Radiotherapy Patients

By

Data support prophylactic use of a PDE-5 inhibitor in men receiving radiotherapy for prostate cancer.

Intermittent Prostate Cancer Chemo Beneficial

By

This approach can reduce adverse events without impairing efficacy.

Post-RARP Weight Gain May Worsen Urinary Incontinence

By

Study finds a significant inverse association between weight changes and incontinence scores in normal-weight patients.

SVI, LNI Have Similar Effect on Prostate Cancer Survival

By

New findings underscore the importance of achieve maximal tumor control in patients with high-risk disease.

Data Support RP for Localized Advanced Prostate Cancer

By

Patients with pT4 tumors had five-year cancer-specific and overall survival rates of 91%.

Prostate Cancer Active Surveillance Reasonable, Long-Term Data Show

By

After more than 10 years of follow-up, 54% of patients progressed, but only one patient died from prostate cancer.

Close Surgical Margins Raise Prostate Cancer Recurrence Risk

By

Compared with negative margins, they are associated with a 51% increased risk of biochemical relapse

Prostate Cancer Radiotherapy Hikes Risk of Second Cancers

By

Study reveals an elevated risk of lung cancer, which researchers called an intriguing finding.

Prostate Cancer Incidence Higher in Men with Autoimmune Disease

By

The incidence is 10 times greater for men with rheumatoid arthritis compared with the general population.

Radical Prostatectomy May Prevent LUTS Progression

By

Following surgery, symptom severity declined significantly and remained stable over 10 years.

Prostate Cancer AS May Be OK Despite Higher PSA

By

Pathologic progression not more likely in patients who start active surveillance with a PSA of 10 ng/mL or higher, study finds.

Black Men on Prostate Cancer AS May Need Closer Follow-Up

By

They are more likely than non-blacks to experience progression and to abandon active surveillance.

Positive Prostate Biopsies Increasing

By

Rate rose from 38.2% in 2005 to 42.5% in 2011.

Black Men Enrollment in Prostate Cancer Trials Low

By

Only 22% of randomized clinical trials reported participation of black men.

Comorbidities Up Other-Cause Mortality Risk in PCa Patients

By

Older men with non-metastatic PCa and who have multiple major comorbidities are at high risk of dying from other causes.

Prostate Cancer Mortality Characterized

By

Study of PCa patients who had equal access to healthcare found that those most likely to die from it had metastatic disease at presentation.

Prostate Cancer Outcomes Good with HIFU

By

Study reveals cancer-specific and metastasis-free survival rates of 97% and 94% with high-intensity focused ultrasound.

Breast Cancer Gene May Have Role in Prostate Cancer

By

A new study suggests that male carriers of the gene mutation are at greater risk of having advanced prostate cancer at the time of diagnosis.

Zoledronic Acid Linked to Early Increase in Sclerostin

Zoledronic Acid Linked to Early Increase in Sclerostin

For postmenopausal women, sclerostin up within two days; returns near to baseline after 360 days.